首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ben,Sidders

第一单位： Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. benjamin.sidders@astrazeneca.com.

作者： Ben,Sidders ^[1] ; Pei,Zhang ^[2] ; Kelly,Goodwin ^[3] ; Greg,O'Connor ^[4] ; Deanna L,Russell ^[4] ; Alexandra,Borodovsky ^[3] ; Joshua,Armenia ^[2] ; Robert,McEwen ^[2] ; Bolan,Linghu ^[4] ; Johanna C,Bendell ^[5] ; Todd M,Bauer ^[5] ; Manish R,Patel ^[6] ; Gerald S,Falchook ^[7] ; Melinda,Merchant ^[8] ; Gayle,Pouliot ^[8] ; J Carl,Barrett ^[4] ; Jonathan R,Dry ^[4] ; Rich,Woessner ^[3] ; Kris,Sachsenmeier ^[4]

作者单位： Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. benjamin.sidders@astrazeneca.com. ^[1] Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. ^[2] Discovery, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts. ^[3] Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts. ^[4] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee. ^[5] Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida. ^[6] Sarah Cannon Research Institute/HealthONE, Denver, Colorado. ^[7] Early Clinical Development, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts. ^[8]